BridgeBio Pharma (BBIO) PT Raised to $95 at Cantor Fitzgerald
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- Nasdaq falls ahead of earnings, economic data while oil rallies
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
Tweet
Share
E-mailGet Alerts BBIO Hot Sheet
Price: $65.75 --0%
Rating Summary:
25 Buy, 3 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 7 | Down: 10 | New: 15
Rating Summary:
25 Buy, 3 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 7 | Down: 10 | New: 15
Join SI Premium – FREE
Cantor Fitzgerald analyst Josh Schimmer raised the price target on BridgeBio Pharma (NASDAQ: BBIO) to $95.00 (from $70.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Telenor ASA (TEL:NO) (TELNY) PT Lowered to NOK145 at JPMorgan
- Bristol-Myers Squibb Co. (BMY) PT Lowered to $60 at Wells Fargo
- Cogstate (CGS:AU) (COGZF) PT Raised to AUD4.15 at Canaccord
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
